Skip to main content

Amniotic Membrane Market Size Worth USD 10.53 Billion in 2032 | Emergen Research

Increasing number of accidents, trauma cases, target patient population, and stem cell research, rising awareness about benefits of AM benefits and government funding and AM transplantation, and advancements in regeneration medicine are key factors driving amniotic membrane market revenue growth.

Vancouver, Dec. 27, 2023 (GLOBE NEWSWIRE) — The global Amniotic Membrane (AM) market size was USD 3.20 Billion in 2022 and is expected to register a rapid revenue CAGR of 12.6% during the forecast period. The market is driven by several key factors, including the increasing incidence of accidents and trauma cases, a growing target patient population, advancements in stem cell research, and rising awareness about the benefits of AM in burns treatment.

Amniotic membrane, a thin tissue layer with antiviral, antimicrobial, and anti-inflammatory properties, finds significant applications in skin transplantation, tissue engineering, and ocular surface reconstruction. The World Health Organization (WHO) reports a surge in burn cases, especially in developing countries, emphasizing the critical role of AM in wound treatment. For instance, in India, nearly one million people suffer burn injuries annually.

Access FREE Sample Copy of the Report @ https://www.emergenresearch.com/request-sample/2610

Furthermore, the rising demand for tissue-based solutions is evident in the increasing number of transplants globally. A noteworthy example is the launch of an awareness campaign by Amniox Medical, Inc. in collaboration with Tissue Tech, Inc., promoting the comprehensive family of human birth tissue-based products for wound healing.

The use of AM in regenerative medicine and cancer therapy is gaining traction, as highlighted by the collaboration between NovaBay Pharmaceuticals and BioStem Technologies. This partnership aims to launch an amniotic tissue allograft, Avenova Allograft, showcasing the promising potential of AM in breakthrough medical treatments.

Despite the optimistic market outlook, challenges such as a shortage of healthcare professionals, escalating medical costs, strict regulatory policies, and complexities in using amniotic membrane may impede revenue growth. Issues like keratitis resulting from AM contamination and the rare possibility of infection transfer during placental birth underscore the need for careful consideration in AM applications.

Product Insights:

In 2022, the cryopreserved segment dominated the global AM market, holding the largest revenue share. Cryopreserved AM, known for its high efficacy and global acceptance rates, is stored at -80°C with glycerol, maintaining its histological and biological characteristics. A notable product in this category is CryoTek’s Amniograft, designed for eye transplant applications, demonstrating its efficacy in reducing eye inflammation and enhancing recovery.

The lyophilization segment is anticipated to register a moderately fast revenue growth rate during the forecast period. Lyophilized AM offers benefits such as extended shelf life, ease of storage, and the preservation of structural and functional integrity, making it suitable for various medical applications, including wound care, ophthalmology, and tissue repair.

Click to Purchase this Report at an Exclusively Discounted Rate @ https://www.emergenresearch.com/request-discount/2610

Application Insights:

Surgical wounds constitute the largest revenue share in the global AM market, driven by the increasing number of surgical procedures and the prevalence of chronic and infectious illnesses. FDA recognition of products like Membrane Wrap, Hydro, designed for treating surgical and other wounds, further boosts the demand for AM in surgical applications.

The ophthalmology segment is expected to experience steady revenue growth, benefiting from AM’s biocompatible graft material with tissue-regenerating and anti-inflammatory properties. AM is used in treating various eye conditions, including corneal disorders, pterygium surgery, and conjunctival reconstruction.

End-Use Insights:

Hospitals lead the end-use segment, accounting for the largest revenue share in the global AM market. The availability of specialized medical professionals, advanced technology, and emergency medical services positions hospitals as key users of AM. Government funding and affiliations with insurance companies contribute to the accessibility of essential healthcare services.

Ambulatory Surgical Centers (ASCs) are poised for the fastest revenue growth, driven by the increasing use of AM in outpatient surgical settings. The ease of use of AM in ASCs facilitates efficient treatment of conditions such as chronic wounds, ocular abnormalities, and joint injuries without the need for a hospital stay.

Regional Insights:

North America emerged as the leader in the global AM market in 2022, attributed to high healthcare expenditure, well-developed healthcare infrastructure, and significant developments by market players. Rising reimbursement for medical products further encourages the adoption of AM, reflecting a robust healthcare ecosystem.

Europe secured the second-largest revenue share, driven by an increasing prevalence of chronic diseases and a growing acceptance of amniotic membranes among healthcare practitioners. Notably, Germany led the market in 2022, supported by the rising incidence of ophthalmologic and orthopedic illnesses.

The Asia Pacific region is expected to witness the fastest revenue growth rate, fueled by rising disposable income, international investments, advancements in healthcare infrastructure, and increasing awareness of regenerative medicine. Key developments, such as the approval of LifeCell International’s birth tissue products, highlight the region’s growing significance in the global AM market.

Direct Order Can Be Placed Through This Link [Exclusive Copy] @ https://www.emergenresearch.com/select-license/2610

Scope of Research

Report DetailsOutcome
Market Size in 2022USD 3.20 Billion
CAGR (2023–2032)12.6%
Revenue Forecast To 2032USD 10.53 Billion
Base Year For Estimation2022
Historical Data2019–2021
Forecast Period2023–2032
Quantitative UnitsRevenue in USD Billion and CAGR in % from 2023 to 2032
Report CoverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments CoveredProduct, application, end-use, and region
Regional ScopeNorth America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Country ScopeU.S., Canada, Mexico, Germany, France, UK, Italy, Spain, Benelux, Rest of Europe, China, India, Japan, South Korea, Rest of APAC, Brazil, Rest of LATAM, Saudi Arabia, UAE, South Africa, Turkey, and Rest of Middle East & Africa
Key Companies ProfiledAmnio Technology, LLC, applied biologics., FzioMed, Inc., Human Regenerative Technologies, LLC, Integra LifeSciences, Corza Ophthalmology, MIMEDX Group, Inc., Skye Biologics Holdings, LLC, BioTissue., Organogenesis Inc., Alliqua BioMedical, Inc., Stryker, VIVEX Biologics, Inc., Merakris Therapeutics, Inc., Thea Pharma Inc., Tissue-Tech, Inc., Allosure, Inc., Katena Products, Inc., DermaSciences, and Laboratoire CCD.

 

Customization Scope10 hours of free customization and expert consultation

Major Companies and Competitive Landscape

The global AM market is fragmented, with many medium and large-sized players accounting for majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing AM products in the market. Some major players included in the global AM market report are:

  • Amnio Technology, LLC
  • applied biologics.
  • FzioMed, Inc.
  • Human Regenerative Technologies, LLC
  • Integra LifeSciences
  • Corza Ophthalmology
  • MIMEDX Group, Inc.
  • Skye Biologics Holdings, LLC
  • BioTissue.
  • Organogenesis Inc.
  • Alliqua BioMedical, Inc.
  • Stryker
  • VIVEX Biologics, Inc.
  • Merakris Therapeutics, Inc.
  • Thea Pharma Inc.
  • Tissue-Tech, Inc.
  • Allosure, Inc.
  • Katena Products, Inc.
  • DermaSciences
  • Laboratoire CCD

Strategic Development

  • On 21 November 2022, Verséa announced the launch of numerous novel products in the ophthalmic area, increasing its offers in the field of eye care. This launch shows the company’s commitment to enhancing eye health and offering new solutions for a wide range of ophthalmic requirements.
  • On 14 February 2022, Amnio Technology developed two innovative dual-layer allograft solutions, and FDA officially acknowledged these products as minimally manipulated with homologous use Human Cells, Tissues, and cellular and tissue-based products (HCT/Ps). This acknowledgment demonstrates their adherence to regulatory requirements as well as their potential in various medical applications.

Browse the complete Global Amniotic Membrane Market Research Report – Industry Analysis, Size, Share, Growth, Trends @ https://www.emergenresearch.com/industry-report/amniotic-membrane-market

Segments Covered in Report

For the purpose of this report, Emergen research has segmented the global AM market on the basis of product, application, end-use, and region:

  • Product Outlook (Revenue, USD Billion; 2019-2032)
    • Cryopreserved
    • Lyophilization
  •  Application Outlook (Revenue, USD Billion; 2019-2032)
    • Surgical Wounds
    • Ophthalmology
    • Others
  •  End-Use Outlook (Revenue, USD Billion; 2019-2032)
    • Hospitals
    • Ambulatory Surgical Centers (ASCs)
    • Specialized Clinics
    • Research Centers & Laboratory
  • Regional Outlook (Revenue, USD Billion; 2019–2032)
    • North America
        • U.S.
        • Canada
        • Mexico
    • Europe
        • Germany
        • France
        • UK
        • Italy
        • Spain
        • Benelux
        • Rest of Europe
    • Asia Pacific
        • China
        • India
        • Japan
        • South Korea
        • Rest of APAC
    • Latin America
        • Brazil
        • Rest of LATAM
    • Middle East & Africa
        • Saudi Arabia
        • UAE
        • South Africa
        • Turkey
        • Rest of Middle East & Africa

Curated Reports You Shouldn’t Miss: Dive In Now!

Food Allergen Testing Market, By Source (Peanut & Soy, Wheat, and Milk), By Technology, By Food Tested, By End-use, and By Region Forecast to 2032

Needles Market, By Product (Suture, Blood Collection, Ophthalmic, Dental, Insufflation, Pen, Biopsy and Aspiration Needles and Others), By Type, By Application, By Delivery Mode, By Material, By End-Use, and By Region Forecast to 2032

Steam Autoclave Market, By Product (Tabletop Steam Autoclaves, Vertical Steam Autoclaves, Floor Standing Steam Autoclaves, Horizontal Steam Autoclaves, and Others), By Technology, By End-Use, and By Region Forecast to 2032

Chronic Lymphocytic Leukemia (CLL) Market, By Type (B-cell, T-Cell, and Natural), By Route of Administration (Parenteral Route and Oral Route), By Therapy, By End-Use Industry, and By Region Forecast to 2032

Smart Inhalers Market, By Product (Dry Powder Inhaler and Metered Dose Inhaler), By Disease Indication [Chronic Obstructive Pulmonary Disease (COPD), Asthma, and Others], By Distribution Channel, By End-Use, and by Region Forecast to 2032

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: https://www.emergenresearch.com/

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Explore Our Blogs and Insights Section: https://www.emergenresearch.com/insights

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.